Stockscreener 앱 받기
6.64
0.15%
0.010
전일 마감가:
$6.63
열려 있는:
$6.7
하루 거래량:
161.96K
Relative Volume:
0.54
시가총액:
$460.60M
수익:
$36.90M
순이익/손실:
$-166.28M
주가수익비율:
-2.0182
EPS:
-3.29
순현금흐름:
$-203.53M
1주 성능:
-0.60%
1개월 성능:
-6.35%
6개월 성능:
-17.00%
1년 성능:
-53.14%
1일 변동 폭
$6.58
$6.80
1주일 범위
$6.30
$7.00
52주 변동 폭
$6.03
$15.43
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
명칭
Bicycle Therapeutics Plc Adr
전화
011441223261503
주소
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
BCYC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
6.64 | 459.91M | 36.90M | -166.28M | -203.53M | -3.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Hold |
| 2025-10-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | 개시 | Stephens | Equal-Weight |
| 2024-09-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 개시 | Cowen | Outperform |
| 2022-07-28 | 개시 | Barclays | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-04-13 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | SVB Leerink | Outperform |
| 2021-12-09 | 개시 | Needham | Buy |
| 2021-09-30 | 개시 | B. Riley Securities | Buy |
| 2021-04-20 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 개시 | Oppenheimer | Outperform |
| 2020-04-17 | 개시 | H.C. Wainwright | Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-09-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-06-17 | 개시 | Canaccord Genuity | Buy |
| 2019-06-17 | 개시 | Goldman | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
| 2019-06-17 | 개시 | Piper Jaffray | Overweight |
모두보기
Bicycle Therapeutics Plc Adr 주식(BCYC)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Operating cash flow per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView — Track All Markets
2025-12-28 | Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BCYC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Investors to Connect - ACCESS Newswire
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2025-12-24 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation | NDAQ:BCYC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Connect - ACCESS Newswire
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - WV News
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages - Defense World
45,950 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Purchased by Dynamic Technology Lab Private Ltd - MarketBeat
Jefferies Financial Group Inc. Boosts Stock Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Coverage Initiated by Analysts at Truist Financial - Defense World
Total revenue of Bicycle Therapeutics Plc Sponsored ADR – HAM:50BA - TradingView
Preferred dividends of Bicycle Therapeutics Plc Sponsored ADR – HAM:50BA - TradingView
Truist Securities initiates coverage on Bicycle Therapeutics stock with Hold rating - Investing.com UK
Investigation Alert: Bicycle Therapeutics plc (BCYC) Under ScrutinyContact Levi & Korsinsky for Details - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - MarketScreener
Acadian Asset Management LLC Buys 572,439 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
A new trading data show Bicycle Therapeutics Plc ADR (BCYC) is showing positive returns. - setenews.com
Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 8.8% Following Analyst Downgrade - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Down 8.8% After Analyst Downgrade - Defense World
Pinnacle Associates Ltd. Sells 42,325 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Analysts Set Expectations for BCYC Q1 Earnings - MarketBeat
EBITDA per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap DownHere's Why - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.8% on Earnings Beat - MarketBeat
Bicycle Therapeutics stock price target raised to $12 from $10 at Citizens By Investing.com - Investing.com South Africa
RBC Capital downgrades Bicycle Therapeutics stock on delayed pipeline progress By Investing.com - Investing.com South Africa
Bicycle Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com South Africa
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results - Placera.se
Bicycle Therapeutics PLC Sponsored ADR $BCYC Position Boosted by Tybourne Capital Management HK Ltd. - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 5.2%Here's Why - MarketBeat
100,291 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Janney Montgomery Scott LLC - Defense World
Global X MLP & Energy Infrastructure ETF $MLPX Holdings Boosted by Janney Montgomery Scott LLC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Receives “Sell (D-)” Rating from Weiss Ratings - Defense World
Financial Comparison: IRIDEX (NASDAQ:IRIX) and Micro Imaging Technology (OTCMKTS:MMTC) - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analyzing Fractyl Health (NASDAQ:GUTS) & Plus Therapeutics (NASDAQ:PSTV) - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 10.5%What's Next? - MarketBeat
A look into Alumis Inc (ALMS)’s deeper side - setenews.com
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 3,231 Shares - MarketBeat
Bicycle Therapeutics Plc Adr (BCYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bicycle Therapeutics Plc Adr 주식 (BCYC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Jan 05 '26 |
Sale |
6.45 |
1,115 |
7,192 |
66,265 |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER |
Jan 05 '26 |
Sale |
6.46 |
3,266 |
21,098 |
161,966 |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER |
Jan 02 '26 |
Sale |
6.80 |
3,045 |
20,706 |
165,232 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Jan 02 '26 |
Sale |
6.80 |
2,827 |
19,224 |
100,275 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Jan 05 '26 |
Sale |
6.45 |
2,367 |
15,267 |
97,908 |
| Milnes Alistair | CHIEF OPERATING OFFICER |
Jan 05 '26 |
Sale |
6.46 |
3,416 |
22,067 |
136,717 |
| Milnes Alistair | CHIEF OPERATING OFFICER |
Jan 02 '26 |
Sale |
6.80 |
3,244 |
22,059 |
140,133 |
| Young Alethia | Chief Financial Officer |
Jan 05 '26 |
Sale |
6.49 |
4,334 |
28,123 |
87,081 |
| Young Alethia | Chief Financial Officer |
Jan 02 '26 |
Sale |
6.80 |
3,289 |
22,365 |
91,415 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Jan 05 '26 |
Sale |
6.46 |
10,989 |
70,989 |
618,996 |
0.90%
자본화:
|
볼륨(24시간):